Barclays Upgrades GlaxoSmithKline (GSK) to Overweight
Tweet Send to a FriendGet Alerts GSK Hot Sheet
Price: $52.22 +0.21%
Rating Summary:
3 Buy, 5 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
3 Buy, 5 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade GSK Now!
Barclays upgraded GlaxoSmithKline (NYSE: GSK) from Equalweight to Overweight.
For an analyst ratings summary and ratings history on GlaxoSmithKline click here. For more ratings news on GlaxoSmithKline click here.
Shares of GlaxoSmithKline closed at $44.56 yesterday, with a 52 week range of $41.68-$47.70.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For an analyst ratings summary and ratings history on GlaxoSmithKline click here. For more ratings news on GlaxoSmithKline click here.
Shares of GlaxoSmithKline closed at $44.56 yesterday, with a 52 week range of $41.68-$47.70.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UBS Survey Shows Signs of Strength for Gilead's (GILD) TAF
- RBC Capital Upgrades TETRA Technologies Inc. (TTI) to Outperform
- CRT Capital Upgrades Standard Pacific (SPF) to Buy
Create E-mail Alert Related Categories
UpgradesRelated Entities
Barclays
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
